| General information | Literature | Expression | Regulation | Mutation | Homolog | Interaction |
Basic Information | |
|---|---|
Gene ID | 9869 |
Name | SETDB1 |
Synonymous | SET domain, bifurcated 1;SETDB1;SET domain, bifurcated 1 |
Definition | ERG-associated protein with SET domain|ERG-associated protein with a SET domain, ESET|H3-K9-HMTase 4|histone H3-K9 methyltransferase 4|histone-lysine N-methyltransferase SETDB1|histone-lysine N-methyltransferase, H3lysine-9 specific 4|lysine N-methyltrans |
Position | 1q21 |
Gene type | protein-coding |
Title | Abstract |
| lung cancer | Aberrant histone methylation is a frequent event during tumor development and progression. KMT1E (also known as SETDB1) is a histone H3K9 methyltransferase that contributes to epigenetic silencing of both oncogenes and tumor suppressor genes in cancer cells. In this report, we demonstrate that KMT1E acts as a metastasis suppressor that is strongly downregulated in highly metastatic lung cancer cells. Restoring KMT1E expression in this setting suppressed filopodia formation, migration, and invasive behavior. Conversely, loss of KMT1E in lung cancer cells with limited metastatic potential promoted migration in vitro and restored metastatic prowess in vivo. Mechanistic investigations indicated that KMT1E cooperates with the TGFbeta-regulated complex SMAD2/3 to repress metastasis through ANXA2. Together, our findings defined an essential role for the KMT1E/SMAD2/3 repressor complex in TGFbeta-mediated lung cancer metastasis. |